Acorda Therapeutics Inc (ACOR)

26.40
NASDAQ : Health Care
Prev Close 26.40
Day Low/High 0.00 / 0.00
52 Wk Low/High 16.40 / 33.00
Avg Volume 846.80K
Exchange NASDAQ
Shares Outstanding 46.41M
Market Cap 1.18B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acorda Stock Jumps Following Patent Challenge Win

Acorda Stock Jumps Following Patent Challenge Win

The challenge was brough by hedge fund manager Kyle Bass.

Acorda To Present At The Cowen And Company 37th Annual Healthcare Conference

Acorda To Present At The Cowen And Company 37th Annual Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present at the Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017 at 1:20 p.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACOR, BAM, BCOR, CMFN, GG, INFO, LBTYA, LBTYK, MXC, WNRL Downgrades: AAN, BCOV, DE, GLAD, MCO, ROCK, RPAI, UEIC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board Of Directors

Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board Of Directors

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Catherine D.

Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More

Analysts' Actions -- Acorda, Restoration Hardware, Humana, Merck and More

Here are Wednesday's top research calls, including upgrades for Acorda and Restoration Hardware, a price target increase for Humana and a price target cut for Merck.

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2016

Acorda Provides Financial And Pipeline Update For Fourth Quarter And Year End 2016

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the fourth quarter and full year ended December 31, 2016.

Acorda Therapeutics Stock Surges on Clinical Trial Results

Acorda Therapeutics Stock Surges on Clinical Trial Results

Acorda Therapeutics announced positive results in a clinical trial for its drug CVT-301.

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.

Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study

Acorda Therapeutics Inhaled Drug Reduces Parkinson's Motor Symptoms in Late-Stage Study

Acorda intends to file for U.S. marketing approval for the drug, CVT-301, in the second quarter, pending results from two long-term safety studies.

Acorda Announces Positive Phase 3 Clinical Trial Results For CVT-301

Acorda Announces Positive Phase 3 Clinical Trial Results For CVT-301

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson's disease experiencing OFF periods.

Acorda Therapeutics To Present At Two Investor Conferences In February

Acorda Therapeutics To Present At Two Investor Conferences In February

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company will present at two investor conferences during February.

Acorda To Host Conference Call To Discuss Fourth Quarter 2016 On February 14, 2017

Acorda To Host Conference Call To Discuss Fourth Quarter 2016 On February 14, 2017

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its fourth quarter 2016 financial results and pipeline updates on Tuesday, February 14 at 8:30 a.

First Week of March 17th Options Trading For Acorda Therapeutics (ACOR)

First Week of March 17th Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

Acorda Announces 2016 AMPYRA Net Sales And 2017 Financial Guidance At J.P. Morgan Healthcare Conference

Acorda Announces 2016 AMPYRA Net Sales And 2017 Financial Guidance At J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg net sales for the fourth quarter of 2016 of $132 million.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Acorda Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will present at the 35th Annual J.

First Week of February 2017 Options Trading For Acorda Therapeutics (ACOR)

First Week of February 2017 Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.

Acorda Therapeutics To Present At The 28th Annual Piper Jaffray Healthcare Conference

Acorda Therapeutics To Present At The 28th Annual Piper Jaffray Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.

In Case You Missed It Monday: Markets Punch Through Record Highs

In Case You Missed It Monday: Markets Punch Through Record Highs

Investors came out swinging Monday, the 40th anniversary of the 'Rocky' movie franchise's debut, as the Trump rally resumed and indices finished higher across the board.

Acorda Stroke Study Fails, Dampening Revenue Growth Plans

Acorda Stroke Study Fails, Dampening Revenue Growth Plans

A mid-stage study of Ampyra in patients with walking difficulties following a stroke "did not show sufficient efficacy" to support further clinical development, Acorda said Monday.

Acorda To Discontinue Development Of Dalfampridine For Treatment Of Post-Stroke Walking Difficulties

Acorda To Discontinue Development Of Dalfampridine For Treatment Of Post-Stroke Walking Difficulties

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the MILESTONE clinical study did not show sufficient efficacy to support further development of dalfampridine to improve post-stroke walking difficulties (PSWD).

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

Acorda Therapeutics To Present At The Stifel 2016 Healthcare Conference

Acorda Therapeutics To Present At The Stifel 2016 Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.

Acorda Provides Financial And Pipeline Update For Third Quarter 2016

Acorda Provides Financial And Pipeline Update For Third Quarter 2016

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the third quarter ended September 30, 2016.

Commit To Purchase Acorda Therapeutics At $7, Earn 15.4% Annualized Using Options

Commit To Purchase Acorda Therapeutics At $7, Earn 15.4% Annualized Using Options

Investors eyeing a purchase of Acorda Therapeutics Inc shares, but tentative about paying the going market price of $19.75/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2017 put at the $7 strike, which has a bid at the time of this writing of 55 cents.

Acorda To Host Conference Call To Discuss Third Quarter 2016 On October 27, 2016

Acorda To Host Conference Call To Discuss Third Quarter 2016 On October 27, 2016

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its third quarter 2016 financial results and pipeline updates on Thursday, October 27 at 8:30 a.

Data From Clinical And Preclinical Trials Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Science Translational Medicine

Data From Clinical And Preclinical Trials Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Science Translational Medicine

Results from Phase 1, Phase 2a and preclinical studies of CVT-301, an inhaled form of levodopa, have been featured in the current edition of Science Translational Medicine.

Acorda Therapeutics, Inc. Has Been Named As One Of The 100 Best Medium Workplaces Based On An Independent Survey By Fortune Magazine And Great Place To Work®. (Photo: Business Wire)

Acorda Therapeutics, Inc. Has Been Named As One Of The 100 Best Medium Workplaces Based On An Independent Survey By Fortune Magazine And Great Place To Work®. (Photo: Business Wire)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the 100 Best Medium Workplaces based on an independent survey by  Fortune  Magazine and Great Place to Work ®.